Implementing genotype-guided Antithrombotic Therapy

• Ansell J , HirshJ, PollerL, BusseyH, JacobsonA, HylekE: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126(3 Suppl.), 204S–233S (2004).
   PubMed Web of Science ®Google Scholar
• Anonymous : 2008 Top 200 generic drugs by total prescriptions. Drug Topics (2009).
   Google Scholar
• McWilliam A , LutterR, and Nardinelli C: Health care savings from personalized medicine using genetic testing: the case of warfarin. AEI-Brookings Joint Center Working Paper 06–23 (2006).
   Google Scholar
• Higashi MK , VeenstraDL, KondoLMet al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA, 287(13), 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Takeuchi F , McGinnisR, BourgeoisSet al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet., 5(3), E1000433 (2009).
   PubMed Web of Science ®Google Scholar
• Cooper GM , JohnsonJA, LangaeeTYet al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Blood, 112(4), 1022–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Kamali F , PirmohamedM: The future prospects of pharmacogenetics in oral anticoagulation therapy.Br. J. Clin. Pharmacol., 61(6), 746–751 (2006).
   PubMed Web of Science ®Google Scholar
• Linder MW , LooneyS, AdamsJEet al. III: Warfarin dose adjustments basedon CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis., 14(3), 227–232 (2002).
   PubMed Web of Science ®Google Scholar
• Rettie AE , WienkersLC, GonzalezFJ, TragerWF, KorzekwaKR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.Pharmacogenetics, 4(1), 39–42 (1994).
   PubMedGoogle Scholar
• Scordo MG , PengoV, SpinaE, DahlML, GusellaM, PadriniR: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.Clin. Pharmacol. Ther., 72(6), 702–710 (2002).
   PubMed Web of Science ®Google Scholar
• Voora D , EbyC, LinderMWet al.: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.Thromb. Haemost., 93(4), 700–705 (2005).
   PubMed Web of Science ®Google Scholar
• Ruaño G , ThompsonPD, VillagraDet al.: High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.Person. Med., 5(3), 225–232 (2008).
   PubMed Web of Science ®Google Scholar
• Aynacioglu AS , SachseCet al., Bozkurt A: Low frequency of defective allelesof cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther., 66(2), 185–192 (1999).
   PubMed Web of Science ®Google Scholar
• Kazui M , NishiyaY, IshizukaTet al.: Identification of the human cytochromeP450 enzymes involved in the twooxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.Drug Metab. Dispos., 38(1), 92–99 (2010).
   PubMed Web of Science ®Google Scholar
• Gaikovitch EA , CascorbiI, MrozikiewiczPMet al.: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.Eur. J. Clin. Pharmacol., 59(4), 303–312 (2003).
   PubMed Web of Science ®Google Scholar
• Bozina N , GranicP, LalicZ, TramisakI, LovricM, Stavljenic-RukavinaA: Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.Croat. Med. J., 44(4), 425–428 (2003).
   PubMed Web of Science ®Google Scholar
• Dorado P , BereczR, NorbertoMJ, YasarU, DahlML, LerenaA: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.Eur. J. Clin. Pharmacol., 59(3), 221–225 (2003).
   PubMed Web of Science ®Google Scholar
• Halling J , PetersenMS, DamkierPet al.: Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.Eur. J. Clin. Pharmacol., 61(7), 491–497 (2005).
   PubMed Web of Science ®Google Scholar
• Wu AH , WangP, SmithAet al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.Pharmacogenomics, 9(2), 169–178 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan-Klose TH , GhanayemBI, BellDAet al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Pharmacogenetics, 6(4), 341–349 (1996).
   PubMedGoogle Scholar
• Stubbins MJ , HarriesLW, SmithG, TarbitMH, WolfCR: Genetic analysis of the human cytochrome P450 CYP2C9 locus.Pharmacogenetics, 6(5), 429–439 (1996).
   PubMedGoogle Scholar
• Yasar U : Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.Biochem. Biophys. Res. Commun. (254), 628–631 (1999).
   PubMed Web of Science ®Google Scholar
• Yang JQ , MorinS, VerstuyftCet al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.Fundam. Clin. Pharmacol., 17(3), 373–376 (2003).
   PubMed Web of Science ®Google Scholar
• Jose R , ChandrasekaranA, SamSSet al.: CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.Fundam. Clin. Pharmacol., 19(1), 101–105 (2005).
   PubMed Web of Science ®Google Scholar
• Hong X , ZhangS, MaoGet al.: CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.Eur. J. Clin. Pharmacol., 61(9), 627–634 (2005).
   PubMed Web of Science ®Google Scholar
• Yu BN , LuoCH, WangDet al.: CYP2C9 allele variants in Chinese hypertension patients and healthy controls.Clin. Chim. Acta, 348(1–2), 57–61 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura M , IeiriI, MamiyaK, UraeA, HiguchiS: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.Ther. Drug Monit., 20(3), 243–247 (1998).
   PubMed Web of Science ®Google Scholar
• Lee SS , KimKM, Thi-LeH, YeaSS, ChaIJ, ShinJG: Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population.Ther. Drug Monit., 27(2), 208–210 (2005).
   PubMed Web of Science ®Google Scholar
• Scott SA , JaremkoM, LubitzSA, KornreichR, HalperinJL, DesnickRJ: CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing.Pharmacogenomics, 10(8), 1243–1255 (2009).
   PubMed Web of Science ®Google Scholar
• Hamdy SI , HiratsukaM, NaraharaKet al.: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.Br. J. Clin. Pharmacol., 53(6), 596–603 (2002).
   PubMed Web of Science ®Google Scholar
• Yasar U , AklilluE, CanaparoRet al.: Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations.Eur. J. Clin. Pharmacol., 58(8), 555–558 (2002).
   PubMed Web of Science ®Google Scholar
• Rosemary J , AdithanC: The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.Curr. Clin. Pharmacol., 2(1), 93–109 (2007).
   PubMedGoogle Scholar
• Dreisbach AW , JapaS, SigelAet al.: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African–Americans with hypertension.Am. J. Hypertens., 18(10), 1276–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Scordo MG , AklilluE, YasarU, DahlML, SpinaE, Ingelman-SundbergM: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.Br. J. Clin. Pharmacol., 52(4), 447–450 (2001).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , CasleyWL, TyndaleRF, SellersEM, Jurima-RometM, LeederJS: Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.Can. J. Physiol. Pharmacol., 79(10), 841–847 (2001).
   PubMed Web of Science ®Google Scholar
• Bravo-Villalta HV , YamamotoK, NakamuraK, BayaA, OkadaY, HoriuchiR: Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.Eur. J. Clin. Pharmacol., 61(3), 179–184 (2005).
   PubMed Web of Science ®Google Scholar
• Vianna-Jorge R , PeriniJA, RondinelliE, Suarez-KurtzG: CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Clin. Pharmacol. Ther., 76(1), 18–26 (2004).
   PubMed Web of Science ®Google Scholar
• LLerena A : Lower frequency of CYP2C9*2 in Mexican–Americans compared with Spaniards.Pharmacogenomics (4), 403–406 (2004).
   Web of Science ®Google Scholar
• Duconge J : Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in hispanics.Ethnicity Disease, 19(4), 390–395 (2009).
   PubMed Web of Science ®Google Scholar
• Reynolds KK , ValdesR Jr, Hartung BR, Linder MW: Individualizing warfarin therapy. Person. Med., 4(1), 11–31 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu Y , ShennanM, ReynoldsKKet al.: estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.Clin.Chem., 53(7), 1199–1205 (2007).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHAet al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood, 106(7), 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Wu AHB : Use of genetic and non-genetic factors in warfarin dosing algorithms.Pharmacogenomics, 7(8), 851–861 (2007).
   Google Scholar
• Mushiroda T , OhnishiY, SaitoSet al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.J. Hum. Genet., 51(3), 249–253 (2006).
   PubMed Web of Science ®Google Scholar
• Wadelius M , SorlinK, WallermanOet al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.Pharmacogenomics J., 4(1), 40–48 (2004).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, DownesKet al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose.Pharmacogenomics J., 5(4), 262–270 (2005).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, ErikssonNet al.: Association of warfarin dose with genes involved in its action and metabolism.Hum. Genet., 121(1), 23–34 (2007).
   PubMed Web of Science ®Google Scholar
• Limdi NA , BeasleyTM, CrowleyMRet al.: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans.Pharmacogenomics, 9(10), 1445–1458 (2008).
   PubMed Web of Science ®Google Scholar
• Hillman MA , WilkeRA, CaldwellMDet al.: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.Pharmacogenetics (14), 539–547 (2004).
   PubMedGoogle Scholar
• Takahashi H , WilkinsonGR, NutescuEAet al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African–Americans.Pharmacogenet. Genomics, 16(2), 101–110 (2006).
   PubMed Web of Science ®Google Scholar
• Schelleman H , ChenJ, ChenZet al.: Dosing algorithms to predict warfarin maintenance dose in Caucasians and African–Americans.Clin. Pharmacol. Ther., 84(3), 332–339 (2008).
   PubMed Web of Science ®Google Scholar
• Rost S , FreginA, IvaskeviciusVet al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.Nature, 427(6974), 537–541 (2004).
   PubMed Web of Science ®Google Scholar
• Li T , ChangCY, JinDY, LinPJ, KhvorovaA, StaffordDW: Identification of the gene for vitamin K epoxide reductase.Nature, 427(6974), 541–544 (2004).
   PubMed Web of Science ®Google Scholar
• Suttie JW : The biochemical basis of warfarin therapy.Adv. Exp. Med. Biol., 214, 3–16 (1987).
   PubMedGoogle Scholar
• Yuan HY , ChenJJ, LeeMTet al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum. Mol. Genet., 14(13), 1745–1751 (2005).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP, GageBFet al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N. Engl. J. Med., 352(22), 2285–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Benson DA , Karsch-MizrachiI, LipmanDJ, OstellJ, WheelerDL: GenBank.Nucleic Acids Res., 36(Database issue), D25–D30 (2008).
   PubMed Web of Science ®Google Scholar
• Tham LS , GohBC, NafzigerAet al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphism in vitamin K epoxide reductase complex and cytochrome P450 2C9.Clin. Pharmacol. Ther., 80, 346–355 (2006).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , BergRL, ZhangKQet al.: Evaluation of genetic factors for warfarin dose prediction.Clin. Med. Res., 5(1), 8–16 (2007).
   PubMedGoogle Scholar
• Thorn CF , KleinTE, AltmanRB: Pharm GKB: the pharmacogenetics and pharmacogenomics knowledge base.Methods Mol. Biol., 311, 179–191 (2005).
   PubMedGoogle Scholar
• Cavallari LH , LangaeeTY, MomaryKMet al.: Genetic and clinical predictors of warfarin dose requirements in African–Americans.Clin. Pharmacol. Ther., 87(4), 459–464 (2010).
   PubMed Web of Science ®Google Scholar
• Pautas E , MoreauC, Gouin-ThibaultIet al.: Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.Clin. Pharmacol. Ther., 87(1), 57–64 (2010).
   PubMed Web of Science ®Google Scholar
• Nakai K , TsuboiJ, OkabayashiHet al.: Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients.Pharmacogenomics, 8(7), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Veenstra DL , YouJH, RiederMJet al.: Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.Pharmacogenet. Genomics, 15(10), 687–691 (2005).
   PubMed Web of Science ®Google Scholar
• Aquilante CL , LangaeeTY, LopezLMet al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Clin. Pharmacol. Ther., 79, 291–302 (2006).
   PubMed Web of Science ®Google Scholar
• D‘Andrea G , D‘AmbrosioRLet al., Di Perna P : A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose–anticoagulant effect of warfarin. Blood, 105(2), 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao F : Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.Clin. Pharmacol. Ther. (76), 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Schelleman H , LimdiNA, KimmelSE: Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Pharmacogenomics, 9(9), 1331–1346 (2008).
   PubMed Web of Science ®Google Scholar
• Hillman MA , WilkeRA, YaleSHet al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.Clin. Med. Res., 3(3), 137–145 (2005).
   PubMedGoogle Scholar
• Anderson JL , HorneBD, StevensSMet al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Circulation, 116(22), 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Caraco Y , BlotnickS, MuszkatM: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy andsafety of anticoagulation: a prospective randomized controlled study.Clin. Pharmacol. Ther., 83(3), 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , AwadT, JohnsonJAet al.: CYP4F2 genetic variant alters required warfarin dose.Blood, 111(8), 4106–4112 (2008).
   PubMed Web of Science ®Google Scholar
• Borgiani P , CiccacciC, ForteVet al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.Pharmacogenomics, 10(2), 261–266 (2009).
   PubMed Web of Science ®Google Scholar
• Morisseau C , HammockBD: Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles.Annu. Rev. Pharmacol. Toxicol., 45, 311–333 (2005).
   PubMed Web of Science ®Google Scholar
• Kaiser J : DNA sequencing. A plan to capture human diversity in 1000 genomes.Science, 319(5862), 395- (2008).
   PubMed Web of Science ®Google Scholar
• Kangelaris KN , BentS, NussbaumRL, GarciaDA, TiceJA: Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.J. Gen. Intern. Med., 24(5), 656–664 (2009).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB, ErikssonNet al.: Estimation of the warfarin dose with clinical and pharmacogenetic data.N. Engl. J. Med., 360(8), 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Fanikos J , Grasso-CorrentiN, ShahR, KucherN, GoldhaberSZ: Major bleeding complications in a specialized anticoagulation service.Am. J. Cardiol., 96(4), 595–598 (2005).
   PubMed Web of Science ®Google Scholar
• Landefeld CS , GoldmanL: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.Am. J. Med., 87(2), 144–152 (1989).
   PubMed Web of Science ®Google Scholar
• Leigh JP , WhiteRH: An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation.Curr. Med. Res. Opin., 23(9), 2071–2081 (2007).
   PubMed Web of Science ®Google Scholar
• Eckman MH , RosandJ, GreenbergSM, GageBF: Cost–effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Ann. Intern. Med., 150(2), 73–83 (2009).
   PubMed Web of Science ®Google Scholar
• Gage BF , YanY, MilliganPEet al.: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).Am. Heart J., 151(3), 713–719 (2006).
   PubMed Web of Science ®Google Scholar
• Frelinger AL et al. III, Furman MI, Linden MD : Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation, 113(25), 2888–2896 (2006).
   PubMed Web of Science ®Google Scholar
• O‘Donnell CJ , LarsonMG, FengDet al.: Genetic and environmental contributions to platelet aggregation: the Framingham heart study.Circulation, 103(25), 3051–3056 (2001).
   PubMed Web of Science ®Google Scholar
• Savi P , PereilloJM, UzabiagaMFet al.: Identification and biological activity of the active metabolite of clopidogrel.Thromb. Haemost., 84(5), 891–896 (2000).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSDet al.: Cytochrome p-450 polymorphisms and response to clopidogrel.N. Engl. J. Med., 360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Pereillo JM , MaftouhM, AndrieuAet al.: Structure and stereochemistry of the active metabolite of clopidogrel.Drug Metab. Dispos., 30(11), 1288–1295 (2002).
   PubMed Web of Science ®Google Scholar
• Giusti B , GoriAM, MarcucciRet al.: Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.Pharmacogenet. Genomics, 17(12), 1057–1064 (2007).
   PubMed Web of Science ®Google Scholar
• Kim KA , ParkPW, HongSJ, ParkJY: The effect of CYP2C19 polymorphismon the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Clin. Pharmacol. Ther., 84(2), 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Hulot JS , BuraA, VillardEet al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood, 108(7), 2244–2247 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoEet al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.Arterioscler. Thromb. Vasc. Biol., 26(8), 1895–1900 (2006).
   PubMed Web of Science ®Google Scholar
• Geisler T , SchaeffelerE, DipponJet al.: CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Pharmacogenomics, 9(9), 1251–1259 (2008).
   PubMed Web of Science ®Google Scholar
• Zanger UM , TurpeinenM, KleinK, SchwabM: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Anal. Bioanal. Chem., 392(6), 1093–1108 (2008).
   PubMed Web of Science ®Google Scholar
• Ruaño G , MakowskiG, WindemuthAet al.: High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety.Person. Med., 3(2), 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Sim SC , RisingerC, DahlMLet al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther., 79(1), 103–113 (2006).
   PubMed Web of Science ®Google Scholar
• Ragia G , ArvanitidisKI, TavridouA, ManolopoulosVG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.Pharmacogenomics, 10(1), 43–49 (2009).
   PubMed Web of Science ®Google Scholar
• Allabi AC , GalaJL, DesagerJP, HeusterspreuteM, HorsmansY: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.Br. J. Clin. Pharmacol., 56(6), 653–657 (2003).
   PubMed Web of Science ®Google Scholar
• Tamminga WJ , WemerJ, OosterhuisB, de Zeeuw RA, de Leij LF, Jonkman JH:The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur. J. Clin. Pharmacol., 57(10), 717–722 (2001).
   PubMed Web of Science ®Google Scholar
• Scordo MG , CaputiAP, D‘ArrigoC, FavaG, SpinaE: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.Pharmacol. Res., 50(2), 195–200 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein JA , IshizakiT, ChibaKet al.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.Pharmacogenetics, 7(1), 59–64 (1997).
   PubMedGoogle Scholar
• Sviri S , ShpizenS, LeitersdorfE, LevyM, CaracoY: Phenotypic–genotypic analysis of CYP2C19 in the Jewish Israeli population.Clin. Pharmacol. Ther., 65(3), 275–282 (1999).
   PubMed Web of Science ®Google Scholar
• Roh HK , DahlML, TybringG, YamadaH, ChaYN, BertilssonL: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.Pharmacogenetics, 6(6), 547–551 (1996).
   PubMedGoogle Scholar
• Scott SA , EdelmannL, KornreichR, ErazoM, DesnickRJ: CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.Pharmacogenomics, 8(7), 721–730 (2007).
   PubMed Web of Science ®Google Scholar
• Ozawa S , SoyamaA, SaekiMet al.: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.Drug Metab. Pharmacokinet., 19(2), 83–95 (2004).
   PubMedGoogle Scholar
• Zand N , TajikN, HoormandM, MoghaddamAS, MilanianI: Allele frequency of CYP2C19 gene polymorphisms in a healthy Iranian population.Iranian J. Pharmacol. Therap.s, 4(2), 124–127 (2005).
   Google Scholar
• Adithan C , GerardN, VasuS, RosemaryJ, ShashindranCH, KrishnamoorthyR: Allele and genotype frequency of CYP2C19 in a Tamilian population.Br. J. Clin. Pharmacol., 56(3), 331–333 (2003).
   PubMed Web of Science ®Google Scholar
• Lamba JK , DhimanRK, KohliKK: Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects.Clin. Pharmacol. Ther., 63(4), 422–427 (1998).
   PubMed Web of Science ®Google Scholar
• He N , YanFX, HuangSLet al.: CYP2C19 genotype and S-mephenytoin 4‘-hydroxylation phenotype in a Chinese Dai population.Eur. J. Clin. Pharmacol., 58(1), 15–18 (2002).
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W , TawaleeA, TassaneeyakulWet al.: Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.Pharmacogenetics, 12(3), 221–225 (2002).
   PubMedGoogle Scholar
• Xiao ZS , GoldsteinJA, XieHGet al.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.J. Pharmacol. Exp. Ther., 281(1), 604–609 (1997).
   PubMed Web of Science ®Google Scholar
• Sugimoto K , UnoT, YamazakiH, TateishiT: Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.Br. J. Clin. Pharmacol., 65(3), 437–439 (2008).
   PubMed Web of Science ®Google Scholar
• Xie HG , KimRB, SteinCM, WilkinsonGR, WoodAJ: Genetic polymorphism of (S)-mephenytoin 4´-hydroxylation in populations of African descent.Br. J. Clin. Pharmacol., 48(3), 402–408 (1999).
   PubMed Web of Science ®Google Scholar
• Herrlin K , MasseleAY, JandeMet al.: Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.Clin. Pharmacol. Ther., 64(4), 391–401 (1998).
   PubMed Web of Science ®Google Scholar
• Bathum L , SkjelboE, MutabingwaTK, MadsenH, HorderM, BrosenK: Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.Br. J. Clin. Pharmacol., 48(3), 395–401 (1999).
   PubMed Web of Science ®Google Scholar
• Persson I , AklilluE, RodriguesF, BertilssonL, Ingelman-SundbergM: S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.Pharmacogenetics, 6(6), 521–526 (1996).
   PubMedGoogle Scholar
• Nowak MP , SellersEM, TyndaleRF: Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.Clin. Pharmacol. Ther., 64(4), 378–383 (1998).
   PubMed Web of Science ®Google Scholar
• Kaneko A , LumJK, YaviongLet al.: High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.Pharmacogenetics, 9(5), 581–590 (1999).
   PubMedGoogle Scholar
• Duconge J , CadillaCL, RentaJYet al.: Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report.P.R. Health Sci. J., 27(4), 357–358 (2008).
   PubMed Web of Science ®Google Scholar
• Linden R , ZiulkoskiAL, TonelloP, WingertM, SoutoAA: Relation between CYP2C19 phenotype and genotype in a group of Brazilian volunteers.Brazilian J. Pharmaceut. Sci., 45(3), 461–467 (2009).
   Web of Science ®Google Scholar
• Luo HR , PolandRE, LinKM, WanYJ: Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study.Clin. Pharmacol. Ther., 80(1), 33–40 (2006).
   PubMed Web of Science ®Google Scholar
• Trenk D , HochholzerW, FrommMFet al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.J. Am. Coll. Cardiol., 51(20), 1925–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O‘connellJR, BlidenKPet al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA, 302(8), 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Collet JP , HulotJS, PenaAet al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet, 373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC, Mary-KrauseMet al.: Genetic determinants of response to clopidogrel and cardiovascular events.N. Engl. J. Med., 360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Frere C , CuissetT, MorangePEet al.: Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.Am. J. Cardiol., 101(8), 1088–1093 (2008).
   PubMed Web of Science ®Google Scholar
• Gilard M , ArnaudB, CornilyJCet al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.J. Am. Coll. Cardiol., 51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM , SpielAO, LangIM, KreinerG, ChristG, JilmaB: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.Am. Heart J., 157(1), 148–145 (2009).
   PubMed Web of Science ®Google Scholar
• Juurlink DN , GomesT, KoDTet al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.CMAJ, 180(7), 713–718 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , CryerB, ContantCet al.; and COGENT Investigators. COGENT: A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at: 21st Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium. San Francisco, CA, USA, 21–26 September 2009.
   Google Scholar
• Wiviott SD , BraunwaldE, McCabeCHet al.: Intensive oral antiplatelet therapyfor reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.Lancet, 371(9621), 1353–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Storey RF : Clopidogrel in acute coronary syndrome: to genotype or not?Lancet, 373(9660), 276–278 (2009).
   PubMed Web of Science ®Google Scholar
• Price MJ : Bedside evaluation of thienopyridine antiplatelet therapy.Circulation, 119(19), 2625–2632 (2009).
   PubMed Web of Science ®Google Scholar
• Bouman H , ParlakEet al., van Werkum J : Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J. Thromb. Haemost., 8(3), 482–488 (2010).
   PubMed Web of Science ®Google Scholar
• Patti G , NuscaA, MangiacapraF, GattoL, D‘AmbrosioA, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol., 52(14), 1128–1133 (2008).
   PubMed Web of Science ®Google Scholar
• Price MJ , EndemannS, GollapudiRRet al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.Eur. Heart J., 29(8), 992–1000 (2008).
   PubMed Web of Science ®Google Scholar
• Marcucci R , GoriAM, PanicciaRet al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.Circulation, 119(2), 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Bliden KP , DichiaraJ, LawalLet al.: The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.J. Am. Coll. Cardiol., 52(7), 531–533 (2008).
   PubMed Web of Science ®Google Scholar
• Gilard M , ArnaudB, CornilyJCet al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.J. Am. Coll. Cardiol., 51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Trenk D , HochholzerW, FrommMFet al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.J. Am. Coll. Cardiol., 51(20), 1925–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt JT , PayneCD, WiviottSDet al.: A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.Am. Heart J., 153(1), 66–16 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , TrenkDet al., Frelinger AL: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention:the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysisin Myocardial Infarction 44 trial. Circulation, 116(25), 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• Montalescot G , WiviottSD, BraunwaldEet al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.Lancet, 373(9665), 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSDet al.: Cytochrome P450 genetic polymorphismsand the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Circulation, 119(19), 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE, McCabeCHet al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes.N. Engl. J. Med., 357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE, AngiolilloDJet al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – thrombolysis in myocardial infarction 38.Circulation, 118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Ferreira IA , MockingAIet al., Feijge MA: Platelet inhibition by insulin is absent in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 26(2), 417–422 (2006).
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Pharma Company. Coumadin® label. 7 August, 2007 revision (2007).
   Google Scholar
• Linkins LA , ChoiPT, DouketisJD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.Ann. Intern. Med., 139(11), 893–900 (2003).
   PubMed Web of Science ®Google Scholar
• King JT Jr, Tsevat J, Lave JR, Roberts MS: Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med. Decis. Making, 25(6), 667–677 (2005).
   PubMed Web of Science ®Google Scholar
• You JH , TsuiKK, WongRS, ChengG: Potential clinical and economic outcomesof CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Clin. Pharmacol. Ther., 86(5), 540–547 (2009).
   PubMed Web of Science ®Google Scholar
• Gage BF , YanY, MilliganPEet al.: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).Am. Heart J., 151(3), 713–719 (2006).
   PubMed Web of Science ®Google Scholar
• van Schie RMF , WadeliusM, KamaliFet al.: Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Pharmacogenomics, 10(10), 1687–1695 (2010).
   Web of Science ®Google Scholar

Websites

• Warfarin Dosing: a free website. www.warfarindosing.org/Source/Home.aspx
   Google Scholar
• Ray T: FDA Clears ParagonDx‘s genetic warfarin assay; firm highlights same-day turnaround. Pharmacogenomics Reporter 6, 19 (2008). www.genomeweb.com/dxpgx/fda-clears-paragondxs-genetic-warfarin-assay-firm-highlights-same-day-turnaround
   Google Scholar
• Kimmel SE, Rosenberg YD, COAG Investigators. Clarification of Optimal Anticoagulation Through Genetics (COAG): A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients. ClinicalTrial.gov website, November 2009. http://clinicaltrials.gov/ct2/show/NCT00839657 (Accessed January112010).
   Google Scholar
• Hudson KL, Javitt GH: The case for genetic testing oversight. BioNews 21 August (2006). www.dnapolicy.org/resources/BioNews_8-21-06.pdf
   Google Scholar
• Secretary‘s Advisory Committee on Genetics Health, and Society: Coverage and Reimbursement of Genetic Tests and Services. Department of Health and Human Services. February (2006). http://oba.od.nih.gov/oba/sacghs/reports/CR_report.pdf
   Google Scholar
• US Department of Health and Human Services. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: In vitro Diagnostic Multivariate Index Assays (2007). www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.pdf
   Google Scholar
• US FDA: FDA clears genetic lab test for warfarin sensitivity (press release). FDA News (2008). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108984.htm
   Google Scholar